Thursday, 08 October 2020 08:36

Dyslipidemia and Atherogenic Index of Plasma among Type 2 Diabetes Mellitus in Dhamar, Yemen Featured

Original Research:

Abdulqawi Ali Al-Shammakh, Abdulelah H. Al-Adhroey, Mohammed A. Al-Kholani, Abdullatif D. Ali, Haidar M. Haidar, Saif N. Alaiwi, Yacup I. Alhamzi, Maljum S. Almonifi, Mokaram A. Alshawish



Background: Dyslipidemia is a recognized major risk factor leading to atherosclerotic cardiovascular disease (CVD) in patients with type2 diabetes mellitus(T2DM). Atherogenic index of plasma (AIP) is expected to be excellent lipid index for predicting CVD.

Aim: This study was aimed to evaluate the prevalence of dyslipidemia and determine atherogenic index of plasma (AIP) among T2DM patients in Dhamar city, Yemen

Methods: This was a cross- sectional study carried out on T2DM patients visiting the outpatient’s clinics at public and private hospitals in Dhamar city during the study time.  A total of 365 patients were enrolled in this study. Sociodemographic and clinical data were obtained using pretested questionnaire.  Blood samples were withdrawn after overnight fast; blood sugar and lipid profiles were spectrophotometrically analyzed.

Results: The overall prevalence of dyslipidemia was found to be 68.5 %. An elevated serum total cholesterol (TC), triglycerides (TG), low density lipoprotein (LDL), low high-density lipoprotein (HDL) and High non-HDL-C were detected in 32.1 %, 38.6 %, 18.6 %, 26.6% and 36.8% of study subjects, respectively.  Multivariable logistic regression revealed significant independent association between dyslipidemia and male diabetic patients (AOR = 1.98; CI = 1.11- 3.53; P = 0.021), unemployed (AOR = 2.077; CI% = 1.15-3.77; P = 0.016) and patients with mean FBS >180 mg/dl (AOR = 2.39; CI% = 1.29-4.42; P = 0.005), respectively. Regarding of AIP, the results showed that 78.36 % of diabetic patients had high risk, 10.68% had a moderate risk and 10.96 % had low risk levels of AIP. Accordingly, AIP was found to be positively correlated with BMI (r = 0.105; P = 0.044), LDL-C (r = 0.138; P = 0.008), and non-HDL-C (r = 0.316; P < 0.001).

Conclusion: The prevalence of dyslipidemia is high among type2 diabetic patients and the majority are at high risk level of AIP. Therefore, an effective screening and therapeutic processes is required to manage dyslipidemia and to protect its serious complication in diabetic patients.

Keywords: Diabetes, Dyslipidemia, Atherogenic index, Yemen


Abdulqawi Ali Al-Shammakh1Abdulelah H. Al-Adhroey2, Mohammed A. Al-Kholani2Abdullatif D. Ali1, Haidar M. Haidar3, Saif N. Alaiwi3, Yacup I. Alhamzi3, Maljum S. Almonifi3, Mokaram A. Alshawish3
1Department of Biochemistry, Faculty of Medicine and Health Sciences, Thamar University, Dhamar, Yemen
2Department of Community Medicine, Faculty of Medicine and Health Sciences, Thamar University, Dhamar, Yemen
3Medical laboratories Graduated Students, Al-Hikma University, Dhamar, Yemen



  1. International Diabetes Federation. IDF Diabetes Atlas, 8th ed. Brussels, Belgium: International Diabetes Federation. 2017.; last accessed on August 15, 2019.

  2. Booth GL, Kapral MK, Fung K, Tu JV. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: A population-based retrospective cohort study. Lancet. 2006;368:29-36. doi: 10.1016/S0140-6736(06)68967-8.

  3. Beckman JA, Paneni F, Cosentino F, Creager MA. Diabetes and vascular disease: Pathophysiology, Clinical consequences, and Medical therapy part II. Eur Heart J. 2013;34:2444-52. doi: 10.1093/eurheartj/eht142.

  4. Mooradian AD. Cardiovascular Disease in Type 2 Diabetes Mellitus: Current Management Guidelines. Arch Intern Med. 2003;163(1):33-40. http:// doi:10.1001/archinte.163.1.33.

  5. Parhofer KG. Interaction between glucose and lipid metabolism: more than diabetic dyslipidemia. Diabetes Metab J. 2015;39:353-362. doi: 10.4093/dmj.2015.39.5.353.

  6. Mooradian, A. Dyslipidemia in Type 2 Diabetes Mellitus. Nat Rev Endocrinol. 2009; 5:150-159. Available from: http://

  7. Mooradian AD, Haas MJ, Wehmeier KR, Wong NCW. Obesity-related changes in high density lipoprotein metabolism. Obesity. 2008;16:1152-1160.

  8. Mooradian AD, Haas MJ and Wong NCW. Transcriptional control of apolipoprotein A-I gene expression in diabetes mellitus. Diabetes. 2004;53:513-520.

  9. Carmena R, Duriez P, Fruchart JC. Atherogenic lipoprotein particles in atherosclerosis. Circulation. 2004;109(23 Suppl 1):III2–III7. doi: 10.1161/01.CIR.0000131511.50734.44.

  10. Rabbani N, Godfrey L, Xue M, Shaheen F, Geoffrion M, Milne R, Thornalley PJ. Glycation of LDL by methylglyoxal increases arterial atherogenicity: A possible contributor to increased risk of cardiovascular disease in diabetes. Diabetes. 2011;60:1973-1980. doi: 10.2337/db11-0085.

  11. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience): Prospective Cardiovascular Munster Study. Am J Cardiol. 1992;70:733-7.

  12. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Mänttäri M, Heinonen OP et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation. 1992;85:37-45.

  13. Ridkar PM, Rifai N, Cook NR, Bradwin G, Buring JE. Non-HDL cholesterol, apolipoproteins A-1 and B-100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA. 2005;294(3):326-333.

  14. Pereira T, Kalahandi R. Dyslipidemia – From Prevention to Treatment. Rijeka. Croatia: In Tech Europe; 2012. Dyslipidemia and cardiovascular risk: lipid ratios as risk factors for cardiovascular disease; 279–302.

  15. Kennel WB. Risk stratification of dyslipidemia: Insights from the Framingham Study. Curr Med Chem Cardiovasc Hematol Agents. 2005;3(3):187-193.

  16. Dobiasov´a M, Urbanov´a Z, and. Sam´anek M.“Relations between particle size of HDL and LDL lipoproteins and cholesterol esterification rate, “Physiological Research. 2005;54:159-165.

  17. Bhardwaj S, Bhattacharjee J, Bhatnagar MK, Tyag S. “Atherogenic index of plasma, Castelli risk index and atherogenic coefficient—new parameters in assessing cardiovascular risk,” International Journal of Pharmacy and biological Sciences. 2013;3(no. 3):359–364.

  18. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010; 33(Suppl 1):S62–S69.

  19. World health Organization. Global status report on noncommunicable diseases 2010. Geneva, Switzerland.

  20. Global Health Observatory. Mean Body Mass Index. World Health Organization (WHO). Available from: gho/ncd/risk_factors/ bmi text/en.

  21. Beevers G, Lip GYH, O'Brien E. ABC of hypertension: Blood Pressure Measurement Part II: Conventional Sphygomonometry: Technique of auscultatory blood pressure measurement. Clinical Review. Br Med J. 2001;322:1110-1114.

  22. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972, 18;499-502. PubMed ID: 4337382.

  23. National Institutes of Health. Detection, Evaluation and Treatment of High Blook Cholesterol in Adults (Adult Treatment Panel III). NIH Publication No. 02-5215. National Institutes of Health; 2002. Available at: /atp3_rpt.htm.

  24. Dobia´s̆ova´ M. “AIP—atherogenic index of plasma as a significant predictor of cardiovascular risk: from research to practice,” Vnitrni Lekarstvi, vol. 52, no. 1, pp. 64–71, 2006.

  25. Niroumand Sh, Khajedaluee M, Khadem-Rezaiyan M, Abrishami M, Juya M, Khodaee Gh, Dadgarmoghaddam M. Atherogenic Index of Plasma (AIP): a marker of cardiovascular disease. Med J Islam Repub Iran. 2015(25July);29:240.

  26. Abdel-Aal NM, Ahmad AT, Froelicher ES, Batieha AM,. Hamza MM, Ajlouni KM. Prevalence of dyslipidemia in patients with type 2 diabetes in Jordan. Saudi Med J. 2008;29(10):1423-1428.

  27. Narindrarangkura P, Bosl W, Rangsin R, Hatthachote P. Prevalence of dyslipidemia associated with complications in diabetic patients: a nationwide study in Thailand. Lipids Health Dis. 2019;18(1):90. Published 2019 Apr 6. doi:10.1186/s12944-019-1034-3.

  28. Mahmoud I, Sulaiman N. Dyslipidaemia prevalence and associated risk factors in the United Arab Emirates: a population based study. BMJ Open 2019;9:e031969. doi:10.1136/bmjopen-2019-031969.

  29. Yan L, Xu MT, Yuan L, Chen B, Xu ZR, Guo QH, et al. Prevalence of dyslipidemia and its control in type 2 diabetes: a multicenter study in endocrinology clinics of China. J Clin Lipidol. 2016;10:150-160. doi: 10.1016/j.jacl.2015.10.009.

  30. Das H, Banik S. Prevalence of dyslipidemia among the diabetic patients in southern Bangladesh: a cross-sectional study. Diabetes Metab Syndr. 2019 Jan - Feb;13(1):252-257. doi: 10.1016/j.dsx.2018.09.006. Epub 2018 Sep 8.

  31. Aljefree N, Ahmed F. Prevalence of cardiovascular disease and associated risk factors among adult population in the Gulf region: a systematic review. Adv Public Health. 2015;2015:1-23.

  32. Bekele S, Yohannes T, Mohammed AE. Dyslipidemia and associated factors among diabetic patients attending Durame General Hospital in Southern Nations, Nationalities, and People’s Region. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2017:10 265-271.

  33. Alshamiri M, Ghanaim MMA, Barter P. Expert opinion on the applicability of dyslipidemia guidelines in Asia and the Middle East. Int J Gen Med. 2018;11:313-322. Published 2018 Jul 18. doi:10.2147/IJGM.S160555.

  34. Mohammad beigi A, Moshiri E, Mohammadsalehi N, Ansari H, Ahmadi A. Dyslipidemia Prevalence in Iranian Adult Men: The Impact of Population-Based Screening on the Detection of Undiagnosed Patients. World J Mens Health. 2015;33(3):167-73.

  35. Chou R, Dana T, Blazina I, Daeges M, Bougatsos C, Jeanne T. Screening for Dyslipidemia in Younger Adults: a systematic review to update the 2008 U.S. Preventive Services Task Force Recommendation. Evidence Synthesis No. 138. AHRQ Publication No. 14-05206-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; 2016.

  36. Jia L, Long S, Fu M, Yan B, Tian Y, Xu Y, et al. Relationship between total cholesterol/high-density lipoprotein cholesterol ratio, triglyceride/high-density lipoprotein cholesterol ratio, and high-density lipoprotein subclasses. Metabolism. 2006;55:1141-8.

  37. Hermans MP, Ahn SA, Rousseau MF. The atherogenic dyslipidemia ratio [log(TG)/HDL-C] is associated with residual vascular risk, beta-cell function loss and microangiopathy in type 2 diabetes females. Lipids Health Dis. 2012;11:132. PubMed Central PMCID: PMC3539971. pmid:23046637.

  38. Khazaal MS. Atherogenic index of plasma as a parameter in predicting cardiovascular risk in males compared to the conventional dyslipidemic indices. Karbala Journal of Medicine. 2013;6:1506-1531.

  39. Niroumand Sh, Khajedaluee M, Khadem-Rezaiyan M, Abrishami M, Juya M, Khodaee Gh, Dadgarmoghaddam M. Atherogenic Index of Plasma (AIP): a marker of cardiovascular disease. Med J Islam Repub Iran. 2015(25July);29:240.

  40. American Diabetes Association. Diabetes Management Guidelines 2013. Available at: Guidelines- Diabetes-Lipids.aspx.

  41. Myat Su Bo, Whye Lian Cheah, Soe Lwin, Tin Moe Nwe, Than Than Win, and Myint Aung. Understanding the Relationship between Atherogenic Index of Plasma and Cardiovascular Disease Risk Factors among Staff of an University in Malaysia. Journal of Nutrition and Metabolism Volume 2018, Article ID 7027624, 6 pages 2

About AMH

Annals of Medicine & Health (AMH) is a peer reviewed medical journal that established and published by a governmental medical faculty titled Thamar University Faculty of Medicine & Health Sciences (TUFMHS). 


Faculty of Medicine & Health Sciences AL-Mohafadhah St. Dhamar City - Yemen

P.O.Box: 87246

Tel Fax: +967 6 509 578

Tel No: +967 6 509 577


Copyright © 2019 Thamar University - Faculty of Medicine and Health Sciences - Annals of Medicine & Health . All Rights Reserved. | Developed By ProSite Yemen